HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit

This article was originally published in The Tan Sheet

Executive Summary

WellPoint Health Networks will not sue FDA if the agency chooses to reject the health insurer's petitions on forcing Rx low- and non-sedating antihistamines to over-the-counter status

You may also be interested in...

FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy

FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers

Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches

FDA likely will face a legal challenge regardless of whether the agency decides to implement mandated Rx-to-OTC switches or chooses a more indirect policy yielding similar results, according to comments made by Aventis and Pfizer executives

Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports

Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts